Evidence map›Paper›PMID 41497163›Full record

ReviewAnnals of medicine and surgery (2012)2026

Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence.

Gbolahan Olatunji, Nicholas Aderinto, Emmanuel Kokori, Michael Awoyinfa, Oluwafemi Ajimotokan, Joan Oluwadamilola Ajayi, Nitin Narayan Rao, Ajayi Oluwatomisin Temidayo, Tejiri Napoleon, Chimezirim Ezeano and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gbolahan OlatunjiDepartment of Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Nicholas AderintoDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Emmanuel KokoriDepartment of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Michael AwoyinfaCollege of Medicine, University of Lagos, Lagos, Nigeria.
Oluwafemi AjimotokanDepartment of Medicine, Babcock University Teaching Hospital, Ogun, Nigeria.
Joan Oluwadamilola AjayiDepartment of Medicine, Kharkiv National Medical University, Kharkiv, Ukraine.
Nitin Narayan RaoDepartment of Medicine, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.
Ajayi Oluwatomisin TemidayoFaculty of Pharmacy, University of Lagos, Lagos, Nigeria.
Tejiri NapoleonDepartment of Medicine, Federal Medical Center, Abeokuta, Nigeria.
Chimezirim EzeanoDepartment of Medicine, University of Nigeria Teaching Hospital, Ituku, Nigeria.
Sulaimon Olaide BukkyAccident and Emergency, Mid Cheshire NHS Trust, Cheshire, UK.
Emmanuel Elorm Nortey-AdomDepartment of Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Sharon Aa-Inir KarboDepartment of Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Israel Charles AbrahamDepartment of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.

Indexed as

clinical trialsHER2-positive colorectal cancertargeted therapyTrastuzumab combinations

Identifiers

PMID41497163
PMCPMC12768115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.